TMS-EEG: An emerging tool to study the neurophysiologic biomarkers of psychiatric disorders
The etiology of psychiatric disorders remains largely unknown. The exploration of the neurobiological mechanisms of mental illness helps improve diagnostic efficacy and develop new therapies. This review focuses on the application of concurrent transcranial magnetic stimulation and electroencephalog...
Gespeichert in:
Veröffentlicht in: | Neuropharmacology 2021-10, Vol.197, p.108574-108574, Article 108574 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The etiology of psychiatric disorders remains largely unknown. The exploration of the neurobiological mechanisms of mental illness helps improve diagnostic efficacy and develop new therapies. This review focuses on the application of concurrent transcranial magnetic stimulation and electroencephalography (TMS-EEG) in various mental diseases, including major depressive disorder, bipolar disorder, schizophrenia, autism spectrum disorder, attention-deficit/hyperactivity disorder, substance use disorder, and insomnia. First, we summarize the commonly used protocols and output measures of TMS-EEG; then, we review the literature exploring the alterations in neural patterns, particularly cortical excitability, plasticity, and connectivity alterations, and studies that predict treatment responses and clinical states in mental disorders using TMS-EEG. Finally, we discuss the potential mechanisms underlying TMS-EEG in establishing biomarkers for psychiatric disorders and future research directions.
This article is part of the special Issue on ‘Stress, Addiction and Plasticity'.
•Psychiatric disorders are often characterized with altered cortical properties.•TMS-EEG can probe cortical excitability, connectivity, and plasticity.•TMS-EEG indices may serve as potential biomarkers for psychiatric disorders. |
---|---|
ISSN: | 0028-3908 1873-7064 |
DOI: | 10.1016/j.neuropharm.2021.108574 |